Search the Newsreel

Accuray Restructures Capital and Governance to Boost Flexibility

Accuray has announced a capital and governance restructuring, including a $55 million convertible preferred stock issuance, cancellation of existing warrants, and a reverse stock split, all aimed at enhancing financial flexibility. The company is also streamlining its board, focusing on operational transformation, and pursuing …

Accuray Enters Agreements With TCW Asset Management to Boost Financial Position, Liquidity

Accuray has entered into new financing agreements with TCW Asset Management Company LLC, replacing its existing term loan and revolving credit facilities. These new agreements are expected to enhance the company's financial position and provide increased liquidity, supporting its strategic initiatives and operations.

Secura Group Limited Provides Earnings Guidance for the Half Year Ended 30 June, 2026

Accuray Inc (ARAY) Financial Health: Profitability & Balance Sheet Analysis

Accuray Inc (ARAY) currently holds a financial score of 7.25, ranking 92 out of 199 in its industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 7.42% year-over-year to $104.84M, and its net profit saw a …

Cura Technologies Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

ARAY|Accuray Inc|Price:0.232|Chg%:-0.011

This article provides a comprehensive stock analysis of Accuray Inc (ARAY), highlighting its current stock score, financial health, valuation, and market performance. It notes the company's stable fundamentals and high growth potential, despite a recent weak stock market performance. The analysis also includes institutional …

Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation

Accuray Incorporated has announced a comprehensive plan to strengthen its financial position and accelerate innovation. This involves a significant financial agreement with TCW Asset Management Company LLC, including deleveraging and an equity investment, along with strategic partnerships with companies like Samsung HME America and …

Beverly Huss and Anne LeGrand resign from Accuray board

Accuray announced that board members Beverly Huss and Anne LeGrand resigned from their positions, effective July 29, 2026. The company stated that their resignations were not due to any disagreement with the company or the board. Information regarding their replacements and specific background details …

Accuray Raises $55M Preferred, Converts $40M Debt; Amends TCW Loan and Cancels Warrants

Accuray (ARAY) announced a recapitalization plan involving a $55.0 million Series A Convertible Preferred Stock agreement, which includes $15.0 million in cash and converts $40.0 million of debt, pending stockholder approval and a reverse stock split. The company also amended its financing with TCW, …

Accuray Incorporated announced that it expects to receive $15 million in funding

Accuray Incorporated is set to receive $15 million in funding through a Securities Purchase Agreement with existing investors. The company will issue 15,000 Series A Convertible Preferred Stocks at $1,000 per share. Dividends on these preferred stocks will accrue at 8% per annum, and …

Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Curanex Pharmaceuticals Inc (CURX), detailing its performance based on various technical indicators and moving averages. It summarizes the buy, sell, and neutral signals from indicators like MACD, RSI, and STOCH, as well as the moving averages (MA5 …

Accuray Inc (ARAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Accuray Inc (ARAY), including its price momentum score of 4.55 within the Healthcare Equipment & Supplies industry. It identifies current support at $0.21 and resistance at $0.28, suggesting suitability for range-bound swing trading. The analysis also details …

Accuray Inc (ARAY) Institutional Confidence

Accuray Inc (ARAY) has an institutional shareholding score of 7.00, placing it 78th in its industry, with 72.22% of shares held by institutions, a 5.61% decrease quarter-over-quarter. James Simons is the largest institutional shareholder. The article also lists major institutional shareholders and their recent …

Accuray Inc (ARAY) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Accuray Inc (ARAY), noting its current risk score of 2.65 and ranking it 145 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics like a beta of 1.34 and various volatility and drawdown figures …

Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Curanex Pharmaceuticals Inc (CURX) financial health, focusing on profitability and balance sheet data. It also includes current stock information, such as market cap and recent trading activity. The content appears to be a stub or an introduction to …

Accuray Inc (ARAY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Accuray Inc (ARAY), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and a list of related ETFs that include ARAY. The data includes specific companies, …

Curanex Pharmaceuticals Inc (CURX) Cash Flow

This article provides a detailed cash flow statement for Curanex Pharmaceuticals Inc (CURX), including operating, investing, and financing cash flows, both quarterly and annually. It also offers explanations of key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and …

Curanex Pharmaceuticals Inc (CURX) Income Statement

This article provides the quarterly income statement for Curanex Pharmaceuticals Inc (CURX), detailing operating expenses, R&D expenses, operating profit, and net income from Q2 2025 to Q1 2026. It also includes frequently asked questions about interpreting income statements and key financial metrics for analyzing …

Accuray Inc (ARAY) Cash Flow - Tradingkey.com

This article provides a detailed cash flow statement for Accuray Inc (ARAY), including quarterly and annual data for operating cash flow, investing cash flow, and financing cash flow. It lists various line items such as net income from continuing operations, capital expenditures, and debt …

Accuray Inc (ARAY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Accuray Inc (ARAY) by business segments and geographical regions, with data updated as of April 6. The company's revenue is segmented into 'Service' and 'Product', with 'Service' contributing a larger proportion. Regional revenue contributions are also …

Curanex Pharmaceuticals Inc (CURX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Curanex Pharmaceuticals Inc (CURX), focusing on its volatility, financial risk, and investment risk. It lists various metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, and Liquidity indicators, although most specific data points are "—" which …

Curanex Pharmaceuticals Inc (CURX) Institutional Confidence

This article provides details on the institutional confidence for Curanex Pharmaceuticals Inc (CURX), listing key shareholders and their respective shareholdings. Notable investors include Liu (Jun), Liu (Chang), Jing (Dian Ying), Citadel Advisors LLC, and Two Sigma Investments, LP. The data also indicates recent changes …

Accuray Inc (ARAY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Accuray Inc (ARAY) has an earnings forecast score of 6.00, ranking 174th in the Healthcare Equipment & Supplies industry. The average analyst price target for ARAY is $3.88, with one analyst currently rating the stock as "Hold". The company is expected to report revenue …

CURX|Curanex Pharmaceuticals Inc|Price:0.188|Chg%:-0.011

This article provides a financial overview of Curanex Pharmaceuticals Inc (CURX), highlighting its latest reported earnings, revenue, and key financial indicators from its income statement, balance sheet, and cash flow statement. It details figures such as EPS, net profit, debt to assets ratio, total …

Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Curanex Pharmaceuticals Inc (CURX) dividend and stock split history, indicating that the company has not distributed any dividends over the past five years. It also includes current stock information such as its price, market capitalization, and performance. No …

ARAY|Accuray Inc|Price:0.238|Chg%:+0.000

This article provides a detailed company profile for Accuray Inc (ARAY), a radiation therapy company. It outlines the company's business scope, including its CyberKnife and TomoTherapy platforms for cancer treatment, and details its financial data and market performance. Key information such as executive shareholdings, …

Price to sales forward of Accuray Incorporated – BX:XEJ

This article provides financial data for Accuray Incorporated (BX:XEJ), specifically its price-to-sales forward ratio. It highlights the company's financial overview within the health technology sector on BX Swiss.

Enterprise value to revenue forward of Accuray Incorporated – NASDAQ:ARAY

The article discusses the enterprise value to revenue forward for Accuray Incorporated (NASDAQ: ARAY). It indicates that financial information specific to this metric would be displayed, likely within a table or chart, but the content provided is primarily navigational and structural rather than data-driven. …

Accuray Incorporated (XEJ) Q2 2025 Earnings Report - Results, Call & Slides

This article provides the Q2 2025 earnings report for Accuray Incorporated (XEJ), detailing an EPS beat of €0.04 with actual EPS at €0.02, compared to a consensus of -€0.02. The company also surpassed revenue expectations, reporting €101.75M against an expected €96.64M, marking an 8.33% …

What Racura Oncology's (ASX:RAC) Latest Options Expiry Means for RAC Shareholders

After a Remarkable Year, Racura Oncology (ASX:RAC) Adds Another Gain

Accuray Incorporated (ARAY) Q2 2026 Earnings: Steep EPS Miss Weighs on Shares - Earnings Power Value

Racura Oncology (ASX:RAC) Draws Investor Interest Amid Recent Developments

Azioni Assicurazioni Generali: upgrade Moody's, partecipazione UniCredit

Arvind Sanger: Cautiously Optimistic on India, Eyeing Earnings Revival - Estimate Accuracy

Racura Oncology Quotes 526,315 New Ordinary Shares at $1.90 Following Placement